Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -10K | -10K | -5K | -75K |
| Operating Income | -812K | -963K | -1M | -898K | -2M |
| EBITDA | -753K | -905K | -1M | -830K | -2M |
| Net Income | -1M | -1M | -1M | -2M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0091
-48.15% today
Window Change
+9.47%
Window
May 29, 2026 → Jun 15, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 12 bars · May 29, 2026 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PreveCeutical Medical Inc. (PRVCF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.01 and up 9.5% across the available one-year price window (May 29, 2026 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +8.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +8.3%, free cash flow -44.3% with operating margin 0.0% and ROIC 100.1%. Stock Foundry combines PRVCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRVCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRVCF Max Drawdown
-51.35%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRVCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$3.8M
-120.1% YoY
Free Cash Flow
$61.9K
+112.9% YoY
Revenue Growth
+0.0%
EPS Growth
+8.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -10K | -10K | -5K | -75K |
| Operating Income | -812K | -963K | -1M | -898K | -2M |
| EBITDA | -753K | -905K | -1M | -830K | -2M |
| Net Income | -1M | -1M | -1M | -2M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59K | 1K | 6K | 16K | 156K |
| Total Assets | 226K | 182K | 189K | 161K | 302K |
| Total Liabilities | 7M | 6M | 5M | 4M | 4M |
| Shareholder Equity | -7M | -6M | -5M | -4M | -4M |
| Total Debt | 4M | 4M | 3M | 3M | 3M |
| Net Debt | 4M | 4M | 3M | 3M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
65K
+115.1% YoY
Capital Expenditures
3K
+95.2% YoY
Free Cash Flow
62K
+112.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
43.2%
Debt / Equity
-0.62x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.